Arbutus Biopharma Corp
ABUS3.480USD
+0.080+2.35%
Close 06/06, 16:00（ET）Quotes delayed by 15 min
666.36MMarket Cap
LossP/E TTM
More Details of Arbutus Biopharma Corp Company
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Company Info
Company codeABUS
Company nameArbutus Biopharma Corp
IPO dateNov 13, 2010
Founded at2017
CEOMs. Lindsay Androski, J.D.
Number of employees44
Security typeOrdinary Share
Fiscal year-endNov 13
Address701 Veterans Circle
CityWARMINSTER
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code18974
Phone16044193200
Websitehttps://www.arbutusbio.com/
Company codeABUS
IPO dateNov 13, 2010
Founded at2017
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Bishop
Mr. Joseph Bishop
Independent Director
Independent Director
--
--
Mr. Matthew Gline
Mr. Matthew Gline
Independent Director
Independent Director
--
--
Mr. Anuj Hasija
Mr. Anuj Hasija
Independent Director
Independent Director
--
--
Mr. Robert Alan Beardsley
Mr. Robert Alan Beardsley
Independent Director
Independent Director
--
--
Ms. Lindsay Androski, J.D.
Ms. Lindsay Androski, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Tuan Nguyen
Mr. Tuan Nguyen
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Bishop
Mr. Joseph Bishop
Independent Director
Independent Director
--
--
Mr. Matthew Gline
Mr. Matthew Gline
Independent Director
Independent Director
--
--
Mr. Anuj Hasija
Mr. Anuj Hasija
Independent Director
Independent Director
--
--
Mr. Robert Alan Beardsley
Mr. Robert Alan Beardsley
Independent Director
Independent Director
--
--
Ms. Lindsay Androski, J.D.
Ms. Lindsay Androski, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Tuan Nguyen
Mr. Tuan Nguyen
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sat, May 17
Update time: Sat, May 17
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Roivant Sciences Ltd.
20.28%
Morgan Stanley Investment Management Inc. (US)
11.85%
Whitefort Capital Management, LP
6.95%
BlackRock Institutional Trust Company, N.A.
5.96%
Two Seas Capital LP
4.94%
Other
50.02%
Shareholder Statistics
Shareholder
Proportion
Roivant Sciences Ltd.
20.28%
Morgan Stanley Investment Management Inc. (US)
11.85%
Whitefort Capital Management, LP
6.95%
BlackRock Institutional Trust Company, N.A.
5.96%
Two Seas Capital LP
4.94%
Other
50.02%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
23.95%
Hedge Fund
21.71%
Corporation
20.28%
Investment Advisor
10.75%
Research Firm
2.47%
Individual Investor
1.64%
Bank and Trust
0.27%
Pension Fund
0.15%
Venture Capital
0.04%
Other
18.75%
Institutional Shareholding
Update time: Sat, Feb 22
Update time: Sat, Feb 22
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
297
147.16M
76.85%
-1.72M
2024Q4
297
147.19M
78.79%
-1.77M
2024Q3
299
144.28M
77.46%
-1.67M
2024Q2
274
139.38M
74.89%
+5.03M
2024Q1
272
125.84M
69.82%
-6.90M
2023Q4
273
121.03M
71.96%
-8.47M
2023Q3
278
113.50M
68.12%
-7.67M
2023Q2
283
108.80M
65.65%
-8.52M
2023Q1
288
105.13M
63.70%
-2.80M
2022Q4
282
96.13M
65.91%
+17.65M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Roivant Sciences Ltd.
38.85M
20.29%
--
--
Feb 25, 2025
Morgan Stanley Investment Management Inc. (US)
21.23M
11.09%
+1.20M
+5.98%
Dec 31, 2024
Whitefort Capital Management, LP
13.31M
6.95%
+66.05K
+0.50%
Feb 20, 2025
BlackRock Institutional Trust Company, N.A.
11.66M
6.09%
+532.48K
+4.78%
Dec 31, 2024
Two Seas Capital LP
8.74M
4.56%
+353.57K
+4.22%
Dec 31, 2024
The Vanguard Group, Inc.
8.95M
4.67%
+62.28K
+0.70%
Dec 31, 2024
State Street Global Advisors (US)
5.03M
2.63%
+619.50K
+14.06%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.48M
1.82%
+33.54K
+0.97%
Dec 31, 2024
View more
Related ETFs
Update time: Fri, Jun 6
Update time: Fri, Jun 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.7%
Invesco NASDAQ Future Gen 200 ETF
0.59%
Hypatia Women CEO ETF
0.21%
iShares Micro-Cap ETF
0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares ESG Aware MSCI USA Small-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
SPDR S&P Biotech ETF
0.06%
iShares Biotechnology ETF
0.05%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.7%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.59%
Hypatia Women CEO ETF
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.1%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
SPDR S&P Biotech ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
